Assenagon Asset Management
TARA icon

Assenagon Asset Management’s Protara Therapeutics TARA Stock Holding History

Assenagon Asset Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$229K Sell
59,954
-507,667
-89% -$2.41M ﹤0.01% 1132
2026
Q1 		$2.96M Buy
567,621
+259,287
+84% +$1.53M ﹤0.01% 705
2025
Q4 		$1.64M Buy
308,334
+912
+0.3% +$5.07K ﹤0.01% 855
2025
Q3 		$1.34M Buy
+307,422
New +$995K ﹤0.01% 882
2024
Q1 		– Sell
-15,831
Closed -$29.7K – 1478
2023
Q4 		$29.7K Hold
15,831
– – ﹤0.01% 1390
2023
Q3 		$26.4K Sell
15,831
-13,220
-46% -$30.3K ﹤0.01% 1367
2023
Q2 		$69.4K Buy
29,051
+11,715
+68% +$34.8K ﹤0.01% 1305
2023
Q1 		$54.3K Hold
17,336
– – ﹤0.01% 1393
2022
Q4 		$46K Sell
17,336
-41,053
-70% -$130K ﹤0.01% 1338
2022
Q3 		$173K Hold
58,389
– – ﹤0.01% 1283
2022
Q2 		$171K Buy
58,389
+14,648
+33% +$53.6K ﹤0.01% 1393
2022
Q1 		$224K Buy
+43,741
New +$230K ﹤0.01% 1341

Other funds holding TARA

GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
AP
Aspect Partners Fairfax, Virginia $268M AUM 22.57% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Assenagon Asset Management's TARA Position: Q2 2026 in Review

Assenagon Asset Management reduced its Protara Therapeutics (TARA) stake by 89% in Q2 2026, selling an estimated $2.41M and leaving 59,954 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #1132.

Assenagon Asset Management first reported a position in TARA in Q1 2022 and has held it in 12 quarters since. The position peaked at $2.96M in Q1 2026. 6 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Assenagon Asset Management held 59,954 shares of Protara Therapeutics worth $229K as of Q2 2026.
  • Assenagon Asset Management sold 507,667 Protara Therapeutics shares in Q2 2026, an estimated $2.41M.
  • Protara Therapeutics made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #1132 holding.
  • Assenagon Asset Management first reported a position in Protara Therapeutics in Q1 2022 and has held it in 12 quarters since.
  • Assenagon Asset Management's Protara Therapeutics position peaked at $2.96M in Q1 2026.
  • 6 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.